FDA allows Houston cancer doctor to resume drug trial
Por um escritor misterioso
Descrição
Federal regulators have lifted a partial hold on a clinical trial performed by Stanislaw
New drug targeting high-risk children's cancer is ready for trials - The Institute of Cancer Research, London
FDA gives controversial doc green light to restart work
FDA issues warning to controversial Houston cancer doctor
Accelerated Approval for Anticancer Products
Drug factory' implants eliminate ovarian, colorectal cancer in mice, Rice News, News and Media Relations
Brian_Wice
UTHealth Houston
Shubham Pant MD Anderson Cancer Center
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study - The Lancet Oncology
FDA panel: Benefit of 'highly anticipated' lung cancer drug can't be interpreted reliably
Houston doctor discovers way to treat pancreatic cancer during clinical trial
Sen. Sanders pushes NIH to rein in drug prices
FDA clears MD Anderson to test skin cancer treatment on humans
Texas Medical Board sanctions controversial cancer doctor Burzynski
de
por adulto (o preço varia de acordo com o tamanho do grupo)
